A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
Status:
Completed
Trial end date:
2017-02-18
Target enrollment:
Participant gender:
Summary
This is a Phase 3, double-blind, randomized study of LJPC-501 (angiotensin II) in adult
patients diagnosed with catecholamine-resistant hypotension (CRH) conducted in multiple
centers globally.